"Considering that according to NIH Director Francis Collins only 2-3 percent of the more than 22,000 submitted applications were funded, TGen has been extremely competitive in securing grants that will help create jobs, advance medical science and provide new treatments for patients with cancer and other serious diseases here in Arizona and beyond," Dr. Trent said. "Having TGen's research recognized after external review as among the top few percent of all applications says a lot about our outstanding physicians and researchers."
According to TGen Physician-in-Chief Dr. Daniel Von Hoff, TGen's success in securing stimulus and other grant funding is evidence that the institute can succeed in a tremendously competitive environment for research and clinical funding. It's a partnership strategy that helps bring funds to Arizona that otherwise might be lost to institutions in other states.
"TGen is poised to translate the discoveries generated in laboratories from both organizations into real solutions for patients," said Dr. Von Hoff. "This is a terrific opportunity to work together and increase our chances of making a difference for our patients."
|Contact: Steve Yozwiak|
The Translational Genomics Research Institute